Perspectives in Head and Neck Medical Oncology.

[1]  S. Kannan,et al.  Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  P. Lyne,et al.  1135OPhase 1b/2 Study (SCORES) assessing safety, tolerability, and preliminary anti-tumor activity of durvalumab plus AZD9150 or AZD5069 in patients with advanced solid malignancies and squamous cell carcinoma of the head and neck (SCCHN) , 2017 .

[3]  J. Machiels,et al.  LBA45_PRPembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial , 2017 .

[4]  Young Uk Kim,et al.  1136ONivolumab and ISA 101 HPV vaccine in incurable HPV-16+ cancer , 2017 .

[5]  David C. Smith,et al.  Epacadostat plus pembrolizumab in patients with advanced RCC: Preliminary phase I/II results from ECHO-202/KEYNOTE-037. , 2017 .

[6]  D. Schadendorf,et al.  Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Bingshu E. Chen,et al.  Effect of Standard Radiotherapy With Cisplatin vs Accelerated Radiotherapy With Panitumumab in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma: A Randomized Clinical Trial , 2017, JAMA oncology.

[8]  S. Liang,et al.  Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. , 2016, The Lancet. Oncology.

[9]  K. Harrington,et al.  Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. , 2016, The New England journal of medicine.

[10]  D. Deschler,et al.  Novel Immunotherapeutic Approaches for Head and Neck Squamous Cell Carcinoma , 2016, Cancers.

[11]  M. Fakih,et al.  Emergency use of uridine triacetate for the prevention and treatment of life‐threatening 5‐fluorouracil and capecitabine toxicity , 2016, Cancer.

[12]  R. Frisina,et al.  Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  C. Loprinzi,et al.  Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. , 2016, The New England journal of medicine.

[14]  J. Lunceford,et al.  Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. , 2016, The Lancet. Oncology.

[15]  R. Berger,et al.  Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Pooled analyses after long-term follow-up in KEYNOTE-012. , 2016 .

[16]  G. Calais,et al.  Long-term Results of a Multicenter Randomized Phase III Trial of Induction Chemotherapy With Cisplatin, 5-fluorouracil, ± Docetaxel for Larynx Preservation. , 2016, Journal of the National Cancer Institute.

[17]  Steven A. Rosenberg,et al.  Cancer : principles & practice of oncology : primer of the molecular biology of cancer/ editors, Vincent T. DeVita, Jr, Theodore S. Lawrence, Steven A. Rosenberg; with 82 contributing authors , 2015 .

[18]  Sue S Yom,et al.  Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  K. Straif,et al.  Betel quid chewing and the risk of oral and oropharyngeal cancers: A meta‐analysis with implications for cancer control , 2014, International journal of cancer.

[20]  E. Vokes,et al.  Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Christopher U. Jones,et al.  Final results of local-regional control and late toxicity of RTOG 9003: a randomized trial of altered fractionation radiation for locally advanced head and neck cancer. , 2014, International journal of radiation oncology, biology, physics.

[22]  S. Faivre,et al.  Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. , 2013, The Lancet. Oncology.

[23]  R. Weber,et al.  Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  F. Khuri,et al.  Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. , 2013, The Lancet. Oncology.

[25]  L. Collette,et al.  Laryngeal preservation with induction chemotherapy for hypopharyngeal squamous cell carcinoma: 10-year results of EORTC trial 24891. , 2012, Annals of Oncology.

[26]  E. Maiello,et al.  Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy. , 2011, The oncologist.

[27]  G. Ramesh,et al.  Mechanisms of Cisplatin Nephrotoxicity , 2010, Toxins.

[28]  Joseph Ciccolini,et al.  Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope? , 2010, Clinical colorectal cancer.

[29]  K. Ang,et al.  Human papillomavirus and survival of patients with oropharyngeal cancer. , 2010, The New England journal of medicine.

[30]  V. Grégoire,et al.  Oropharyngeal carcinoma related to human papillomavirus , 2010, BMJ : British Medical Journal.

[31]  S. Spencer,et al.  Dosimetric factors associated with long-term dysphagia after definitive radiotherapy for squamous cell carcinoma of the head and neck. , 2010, International journal of radiation oncology, biology, physics.

[32]  N. Ikeda,et al.  Pulmonary metastasectomy for pulmonary metastases of head and neck squamous cell carcinomas. , 2009, The Annals of thoracic surgery.

[33]  G. Calais,et al.  Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. , 2009, Journal of the National Cancer Institute.

[34]  J. Pignon,et al.  Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[35]  J. Moon,et al.  Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: A Southwest Oncology Group phase II trial (S0216) , 2009, Head & neck.

[36]  J. Langendijk,et al.  High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[37]  S. H. Cheng,et al.  Use of combined molecular biomarkers for prediction of clinical outcomes in locally advanced tonsillar cancers treated with chemoradiotherapy alone , 2009, Head & neck.

[38]  V. Grégoire,et al.  Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Masahiro Hiraoka,et al.  Stereotactic body radiotherapy for oligometastatic lung tumors. , 2008, International journal of radiation oncology, biology, physics.

[40]  C. Bokemeyer,et al.  Platinum-based chemotherapy plus cetuximab in head and neck cancer. , 2008, The New England journal of medicine.

[41]  R. Haddad,et al.  Radiation treatment breaks and ulcerative mucositis in head and neck cancer. , 2008, The oncologist.

[42]  A. Garden,et al.  Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  M. Poulsen,et al.  Predictors of acute grade 4 swallowing toxicity in patients with stages III and IV squamous carcinoma of the head and neck treated with radiotherapy alone. , 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[44]  T. Gorlia,et al.  Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. , 2007, The New England journal of medicine.

[45]  A. Markoe,et al.  Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. , 2007, The New England journal of medicine.

[46]  J. Berlin,et al.  High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  D. Ronis,et al.  Variables associated with feeding tube placement in head and neck cancer. , 2006, Archives of otolaryngology--head & neck surgery.

[48]  Christopher U. Jones,et al.  Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. , 2006, The New England journal of medicine.

[49]  N. Slevin,et al.  Evaluating predictive factors for determining enteral nutrition in patients receiving radical radiotherapy for head and neck cancer: a retrospective review. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[50]  M. van Glabbeke,et al.  Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501) , 2005, Head & neck.

[51]  W. Ahrens,et al.  Occupation, exposure to polycyclic aromatic hydrocarbons and laryngeal cancer risk , 2005, International journal of cancer.

[52]  J. Cooper,et al.  Chemoradiation after surgery for high-risk head and neck cancer patients: how strong is the evidence? , 2005, The oncologist.

[53]  Armando Santoro,et al.  Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.

[54]  J. Jacobs,et al.  Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. , 2004, The New England journal of medicine.

[55]  R. Weber,et al.  Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. , 2003, The New England journal of medicine.

[56]  J. Bourhis,et al.  Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data , 2000, The Lancet.

[57]  G. Calais,et al.  Randomized Trial of Radiation Therapy Versus Concomitant Chemotherapy and Radiation Therapy for Advanced-Stage Oropharynx Carcinoma. , 1999, Journal of the National Cancer Institute.

[58]  A. Huang,et al.  Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. , 1998, The New England journal of medicine.

[59]  J. Cooper,et al.  Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  L. Tuason,et al.  A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: Preliminary results , 1997, Head & neck.

[61]  D. Thomas,et al.  Work in dry cleaning and the incidence of cancer of the oral cavity, larynx, and oesophagus. , 1997, Occupational and environmental medicine.

[62]  F. Chauvin,et al.  The pathophysiological mechanism of fluid retention in advanced cancer patients treated with docetaxel, but not receiving corticosteroid comedication. , 1997, British journal of clinical pharmacology.

[63]  L. Collette,et al.  Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. , 1996, Journal of the National Cancer Institute.

[64]  N. Goldstein,et al.  Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[65]  W. Curran,et al.  Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas. , 1995, International journal of radiation oncology, biology, physics.

[66]  L. Eapen,et al.  Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  L. Kalish,et al.  Concurrent radiation therapy and chemotherapy for locally unresectable squamous cell head and neck cancer: an Eastern Cooperative Oncology Group pilot study. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  J. Johnson,et al.  Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. , 1993, The New England journal of medicine.

[69]  L. Hutchins,et al.  Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  F. de Vathaire,et al.  Neoadjuvant chemotherapy consisting of cisplatin and continuous infusions of bleomycin and 5‐fluorouracil for advanced head and neck cancer. The need for a new stratification for stage IV (MO) disease , 1991, Cancer.

[71]  W. Hong,et al.  Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. , 1991, The New England journal of medicine.

[72]  T. Siegal,et al.  Cisplatin‐induced peripheral neuropathy. Frequent off‐therapy deterioration, demyelinating syndromes, and muscle cramps , 1990, Cancer.

[73]  J. Suen,et al.  Cisplatin potentiation of radiotherapy. Long-term follow-up. , 1985, Archives of otolaryngology.

[74]  S. Shapshay,et al.  A prospective randomized trial of methotrexate versus cisplatin in the treatment of recurrent squamous cell carcinoma of the head and neck , 1983, Cancer.

[75]  V. Devita,et al.  Comprar Cancer: Principles & Practice of Oncology, 2ª Ed. Primer Of The Molecular Biology Of Cancer | Vincent T. DeVita Jr. | 9781496310637 | Lippincott Williams & Wilkins , 2015 .

[76]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[77]  D. Hollywood,et al.  Toxicity of cetuximab versus cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer (LAHNSCC). , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[78]  Jordi Giralt,et al.  Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. , 2010, The Lancet. Oncology.

[79]  W. Gradishar,et al.  American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  Jacques Bernier,et al.  Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. , 2004, The New England journal of medicine.

[81]  J. Ensley,et al.  An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.